Co-Diagnostics, Inc.

DB:C97 Stock Report

Market Cap: €30.2m

Co-Diagnostics Valuation

Is C97 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of C97 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate C97's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate C97's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for C97?

Key metric: As C97 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for C97. This is calculated by dividing C97's market cap by their current revenue.
What is C97's PS Ratio?
PS Ratio4.3x
SalesUS$7.32m
Market CapUS$31.61m

Price to Sales Ratio vs Peers

How does C97's PS Ratio compare to its peers?

The above table shows the PS ratio for C97 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3x
NN6 NanoRepro
5.5xn/a€19.6m
AAQ1 aap Implantate
1.9xn/a€22.4m
GME Geratherm Medical
1x1.9%€21.0m
PUS PULSION Medical Systems
3.8xn/a€134.4m
C97 Co-Diagnostics
4.3x-94.5%€31.6m

Price-To-Sales vs Peers: C97 is expensive based on its Price-To-Sales Ratio (4.3x) compared to the peer average (3.1x).

Price to Sales Ratio vs Industry

How does C97's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$830.14m
PHH2 Paul Hartmann
0.3xn/aUS$781.42m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
C97 4.3xIndustry Avg. 3.6xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: C97 is expensive based on its Price-To-Sales Ratio (4.3x) compared to the European Medical Equipment industry average (3.7x).

Price to Sales Ratio vs Fair Ratio

What is C97's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

C97 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.3x
Fair PS Ratio0.006x

Price-To-Sales vs Fair Ratio: C97 is expensive based on its Price-To-Sales Ratio (4.3x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sensus Healthcare

US$143.9m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

5TX

US$8.25

7D

4.4%

1Y

263.8%

Shandong Weigao Group Medical Polymer

HK$20.2b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-1.9%

1Y

-37.7%

LNA Santé

€240.3m

Engages in the management and operation of health establishments.

2N3

€23.00

7D

1.5%

1Y

17.7%